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Background
In the recent years there have been major advances in the
field of cancer immunology and the existence of a dichot-
omy between immunologically active and quiescent
tumor phenotypes has been recognized in several can-
cers. The activation of a Th1 immune signature has been
shown to confer better prognosis and likelihood to
respond to immunotherapy. However, whether such
dichotomy depends on the genetic make-up of individual
cancers is not known yet. In melanoma, BRAF and NRAS
mutations are commonly acquired during tumor progres-
sion. Although the oncogenic potential of BRAF and
NRAS alterations has been attributed to reduced apopto-
sis, increased invasiveness and increased metastatic beha-
vior, the role of BRAF and NRAS in the immunological
landscape of cutaneous melanoma has been poorly inves-
tigated and the effects of BRAF and NRAS mutations on
global gene expression remain to be understood. We
explored the role of BRAF and NRAS mutations at the
transcriptome level and in influencing the immune phe-
notype (based on a classification previously identified by
our group).
Materials and methods
One-hundred-thirteen pre-treatment snap frozen tumor
biopsies were collected from patients treated at the Surgery
Branch, NCI (Bethesda, Maryland) and processed for DNA
and RNA isolation. Each sample underwent microarray
analysis and BRAF and NRAS genotyping. Allele-specific
PCR was also performed in order to exclude low-frequency
mutations. Fifteen melanoma cell lines were also tested for
BRAF and NRAS mutation by Sanger sequencing and
RNA-sequencing.
Results
Comparison between BRAF and NRAS mutant versus wild
type samples identified mostly constituents or regulators
of MAPK and related pathways. Initially, we postulated
that there might be a common MAPK activation signature
resulting from either BRAF or NRAS mutation; however,
we found no overabundance of discriminatory genes for
the combined group of samples displaying either BRAF or
NRAS mutations. This suggests that the transcriptional
consequences resulting from mutations of BRAF or NRAS
might be different, although there was overlapping of
some genes, presumably due to their differential capacity
to receive input signals and transduce them through dif-
ferent effectors.
When testing gene lists discriminative of BRAF, NRAS
and MAPK alterations, we found that 112 BRAF-specific
transcripts were able to distinguish the two immune-
related phenotypes already described in melanoma, with
the poor phenotype associated mostly with BRAF muta-
tion. Noteworthy, such association was stronger in sam-
ples displaying low BRAF mRNA expression. However,
when testing NRAS mutation, we were not able to find the
same association. Class comparison between BRAF mutant
samples with high and low expression of the same gene
identified 6296 transcripts. Functional interpretation ana-
lysis showed that these 6296 transcripts were associated to
IL-2 and JAK/Stat signaling pathways, supporting the
immunoregulatory role of BRAF. Additionally, fifteen mel-
anoma cell lines were also tested by BRAF and NRAS
DNA genotyping and RNA-sequencing. Interestingly, we
found that among 8 cell lines BRAF mutated (V600E),
three of them expressed BRAF at low level and may have
preferential wild type allele selection at the RNA level.
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Conclusion
In conclusion we provide novel insights into the effect of
BRAF and NRAS mutations on gene expression according
to the immune classification. However, further deeper ana-
lyses are warranted to understand the mechanisms behind
the association of BRAF mutation with a poor immune
phenotype and also behind BRAF low expression and wild
type allele selection at the RNA level.
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